| Literature DB >> 20430316 |
Lars Neeb1, Jannis Meents, Uwe Reuter.
Abstract
Migraine is a debilitating disorder of the CNS. Although therapeutic options for migraine attacks have tremendously advanced with the development of triptans more than a decade ago, several conditions (such as vascular disease) restrict their use. Moreover, some patients do not respond to triptans and other currently available medications. Therefore, treatment alternatives are needed. Study data show that 5-HT(1F) receptor agonists successfully abort migraine attacks. These data also suggest a favorable vascular side-effect profile of these substances, which could be beneficial for migraine treatment in subjects with cardiac or vascular disease. We discuss the current knowledge of 5-HT(1F) receptor-mediated effects, in part by comparing them to triptans, and we also summarize data from basic research and clinical trials. Copyright 2010 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier Inc. All rights reserved.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20430316 PMCID： PMC5084098 DOI： 10.1016/j.nurt.2010.03.003
Source DB: PubMed Journal: Neurotherapeutics ISSN： 1878-7479 Impact factor: 7.620